Regimen Reference Order – MULTI – entrectinib

ARIA: MULTI - [entrectinib]

Planned Course: Orally once daily until disease progression or unacceptable toxicity (1 cycle = 30 days)

Indication for Use: Neurotrophic Tyrosine Receptor Kinase (NTRK) positive tumors

Proceed with treatment if:

- ANC equal to or greater than 1×10^9 /L AND Platelets equal to or greater than 100×10^9 /L
- AST/ALT equal to or less than 5 times the upper limit of normal
- Total bilirubin equal to or less than 1.5 times the upper limit of normal
- Uric acid equal to or less than the upper limit of normal
- Contact Physician if parameters not met

Pre-treatment Requirements				
Drug	Dose	CCMB Administration Guideline		
Not Applicable				

Drug	Dose	CCMB Administration Guideline
entrectinib	600 mg	Orally once daily with or without food
		Swallow whole
		(Self-administered at home)

REQUIRED MONITORING

Cardiac monitoring

- EKG
 - Prior to Cycles 1 and 2
 - As clinically indicated for subsequent cycles to assess for atrial fibrillation at prescriber's discretion
- LVEF
 - LVEF monitoring is not required at baseline for all patients. In patients with symptoms or known risk factors for congestive heart failure, cardiac investigations will occur at prescriber's discretion
 - o As clinically indicated for subsequent cycles to assess for congestive heart failure at prescriber's discretion

Cycle 1

Day 1

• CBC, serum creatinine, urea, electrolytes, liver enzymes, LDH, total bilirubin, uric acid and albumin as per Physician Orders

Day 15

• CBC, liver enzymes, LDH, total bilirubin and uric acid as per Physician Orders



Cycle 2

Day 1

• CBC, serum creatinine, urea, electrolytes, liver enzymes, LDH, total bilirubin, uric acid and albumin as per Physician Orders

Cycle 3

Day 1

• CBC, serum creatinine, urea, electrolytes, liver enzymes, LDH, total bilirubin, uric acid and albumin as per Physician Orders

Cycle 4 and Onwards

- CBC, serum creatinine, urea, electrolytes, liver enzymes, LDH, total bilirubin, uric acid and albumin
 - At the physician's discretion but no less than every 3 months

Recommended Support Medications				
Drug	Dose	CCMB Administration Guideline		
None required				

INSTRUCTIONS FOR PATIENT

- entrectinib has potential for drug-drug interactions. Patients should notify clinic prior to starting any new medication
- Avoid grapefruit and grapefruit juice, Seville oranges (i.e. orange marmalade) and starfruit
- Patients should be counseled on potential for vision changes and cognitive changes with entrectinib
- Reinforce applicable safe handling precautions of medications, blood and body fluids while on entrectinib

ADDITIONAL INFORMATION

- entrectinib can cause hyperuricemia
- entrectinib increases the risk of fractures
- entrectinib can prolong QT interval and cause congestive heart failure
- entrectinib will be dispensed by CCMB Pharmacy

